GENFF.US Genflow Biosciences plc
- Market cap
- USD 26.8M
- P/E
- -
- P/B
- 105.59x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is GENFF.US undervalued?
Graham numberThe Graham number of Genflow Biosciences plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genflow Biosciences plc fundamental analysis
No fundamental analysis for Genflow Biosciences plc yet.
Genflow Biosciences plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genflow Biosciences plc
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapies in the United Kingdom, Belgium, and the United States. It develops drugs in pre-clinical trial stage, including GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion for the treatment of metabolic associated steatohepatitis; GF-1003, a topical delivery of SIRT6 to the skin; GF-1004, a non-human pipeline anti-aging …
Full company profileGenflow Biosciences plc financial statements
Genflow Biosciences plc annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | - | -938K | -1.33M | -1.86M | -1.59M | -1.42M |
| EBITDA | - | -988K | -1.33M | -1.86M | -1.59M | -1.42M |
| Net Income | - | -988K | -1.34M | -1.86M | -1.59M | -1.42M |
| EPS | - | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| Balance Sheet | ||||||
| Total Assets | - | 277K | 2.62M | 1.07M | 386K | 452K |
| Total Liabilities | - | 221K | 251K | 572K | 789K | 1.00M |
| Shareholders' Equity | - | 55.1K | 2.37M | 500K | -403K | -551K |
| Cash & Short-term Investments | - | 224K | 2.36M | 684K | 279K | 112K |
| Cash Flow | ||||||
| Operating Cash Flow | -439K | -815K | -1.37M | -1.66M | -1.08M | -1.44M |
| Capital Expenditure | 0.00 | 0.00 | 2.48K | 2.44K | 0.00 | 0.00 |
| Free Cash Flow | - | -747K | -1.37M | -1.66M | -1.08M | -1.44M |
| Ratios | ||||||
| ROE | - | -1,792.7% | -56.4% | -372.3% | - | - |
| ROA | - | -357.3% | -51.0% | -173.6% | -411.3% | -313.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Genflow Biosciences plc dividends
Genflow Biosciences plc has not paid dividends in the last 6 fiscal years.
Who owns Genflow Biosciences plc
- Insiders 46.47%
- Institutions 2.63%
- Public & others 50.90%
- Shares outstanding 595M
- Free float 326M
Genflow Biosciences plc company profile
- Company name
- Genflow Biosciences plc
- Ticker
- GENFF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Fiscal year end
- December
- Address
- 6 Heddon Street, London, United Kingdom, W1B 4BT
- Website
- genflowbio.com
About Genflow Biosciences plc
Genflow Biosciences plc, together with its subsidiaries, engages in the research and development of gene therapies in the United Kingdom, Belgium, and the United States. It develops drugs in pre-clinical trial stage, including GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion for the treatment of metabolic associated steatohepatitis; GF-1003, a topical delivery of SIRT6 to the skin; GF-1004, a non-human pipeline anti-aging for veterinary use; GF-1005 for the treatment of mitochondrial dysfunction and sarcopenia; and GF-1006, an ophthalmology mRNA cent SIRT6 for the treatment of cornea pathologies and glaucoma. The company was founded in 2020 and is headquartered in London, the United Kingdom.
Genflow Biosciences plc management
1- Dr. Eric Jean Leire M.D., MBAFounder, CEO & Executive Director · born 1958